Spots Global Cancer Trial Database for isatuximab sar650984
Every month we try and update this database with for isatuximab sar650984 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients | NCT03275285 | Plasma Cell Mye... | isatuximab SAR6... carfilzomib dexamethasone | 18 Years - | Sanofi | |
| A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | NCT04458831 | Plasma Cell Mye... | isatuximab SAR6... Pomalidomide Dexamethasone Carfilzomib | 18 Years - | Sanofi | |
| A Study of Isatuximab-based Therapy in Participants With Lymphoma | NCT03769181 | Lymphoma | isatuximab SAR6... cemiplimab REGN... | 12 Years - | Sanofi | |
| Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | NCT03637764 | Neoplasm | Isatuximab SAR6... Atezolizumab | 18 Years - | Sanofi | |
| SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients | NCT02283775 | Plasma Cell Mye... | Isatuximab SAR6... Pomalidomide Dexamethasone | 18 Years - | Sanofi | |
| A Study of Isatuximab-based Therapy in Participants With Lymphoma | NCT03769181 | Lymphoma | isatuximab SAR6... cemiplimab REGN... | 12 Years - | Sanofi | |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | NCT03194867 | Plasma Cell Mye... | Isatuximab SAR6... Cemiplimab REGN... | 18 Years - | Sanofi | |
| Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant | NCT03319667 | Plasma Cell Mye... | Isatuximab SAR6... Bortezomib Lenalidomide Dexamethasone | 18 Years - 80 Years | Sanofi | |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | NCT03194867 | Plasma Cell Mye... | Isatuximab SAR6... Cemiplimab REGN... | 18 Years - | Sanofi | |
| Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients | NCT02812706 | Multiple Myelom... | Isatuximab SAR6... | 20 Years - | Sanofi | |
| Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma | NCT03733717 | Multiple Myelom... | Isatuximab SAR6... | 18 Years - | Sanofi | |
| A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma | NCT04270409 | Plasma Cell Mye... | Isatuximab SAR6... Lenalidomide Dexamethasone Montelukast or ... Acetaminophen Diphenhydramine... Methylprednisol... | 18 Years - | Sanofi | |
| SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients | NCT02283775 | Plasma Cell Mye... | Isatuximab SAR6... Pomalidomide Dexamethasone | 18 Years - | Sanofi | |
| Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | NCT01084252 | Hematological M... | Isatuximab SAR6... Dexamethasone Dexamethasone | 18 Years - | Sanofi | |
| Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant | NCT03319667 | Plasma Cell Mye... | Isatuximab SAR6... Bortezomib Lenalidomide Dexamethasone | 18 Years - 80 Years | Sanofi | |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | NCT03194867 | Plasma Cell Mye... | Isatuximab SAR6... Cemiplimab REGN... | 18 Years - | Sanofi | |
| Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma | NCT03733717 | Multiple Myelom... | Isatuximab SAR6... | 18 Years - | Sanofi | |
| SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients | NCT01749969 | Plasma Cell Mye... | isatuximab SAR6... lenalidomide dexamethasone | 18 Years - | Sanofi |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
